This is an investigational study. Ibrutinib is FDA approved and commercially available for the treatment of patients with mantle cell lymphoma and in patients with CLL who have received at least 1 prior treatment. Its use in this study is investigational. Rituximab is FDA approved and commercially available for the treatment of CLL. The combination of rituximab and ibrutinib is investigational.